Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century

American Journal of Public Health

Volumn 89, Issue 1, 1999, Pages 98-101

  Annas, George J ^a   Elias, Sherman ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ARTICLE; DISASTER; ERYTHEMA NODOSUM; HISTORY OF MEDICINE; HUMAN; LEPROSY; POSTMARKETING SURVEILLANCE; RISK BENEFIT ANALYSIS; TECHNOLOGY; TERATOGENICITY;

EID: 0032976445     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.89.1.98     Document Type: Article

References (25)

1. Hawthorn J. Cunning Passages: New Historicism, Cultural Materialism, and Marxism in the Contemporary Literary Debate. London, England: Arnold; 1996.
2. Beesley L, Gracie A, Lightoller C, Bride H. The Story of the Titanic as Told by Its Survivors. Mineola, NY: Dover Publications Inc; 1960:94.
3. Bernstein A. Formed by thalidomide: mass torts as a false cure for toxic exposure. Columbia Law Review. 1997;97:2153-2176.
4. Insight Team of the Sunday Times of London. Suffer the Children: The Story of Thalidomide. New York, NY: Viking Press; 1979.
5. Dally A. Thalidomide: was the tragedy preventable? Lancet. 1998;351:1197-1199.
6. Lenz W. Klinische Misbildüngen nach Medikament: einnahme Während der Gravidität? Dtsch Med Wochenschr. 1961;86:2555-2565.
7. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358-1363.
8. Newman CGH. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol. 1986;13:555-573.
9. Smithells RW, Newman CHG. Recognition of thalidomide defects. J Med Genet. 1992; 29:716-723.
10. Elias SE, Annas GJ. Reproductive Genetics and the Law. St. Louis, Mo: Mosby-Yearbook; 1987:207.
11. Koren G, Pastusak A, Shinya I. Drugs in pregnancy. N Engl J Med. 1998;338:1126-1137.
12. Castilla EE, Ashton-Prolla P, Barreda-Megia E, et al. Thalidomide: a current teratogen in South America. Teratology. 1996;54:273-277.
13. Stolberg SG. Thalidomide wins FDA's approval. New York Times. July 17, 1998:1.
14. Food and Drug Administration. FDA Talk Paper on Thalidomide. Washington, DC: Public Health Service; July 16, 1998.
15. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 1997; 336:1487-1493.
16. Shulman SR. The broader message of Accutane. Am J Public Health. 1989;79:1565-1568.
17. Roe v Wade, 410 U.S. 113 (1973).
18. Garrow DJ. Liberty & Sexuality: The Right to Privacy and the Making of Roe v. Wade. New York, NY: Macmillan; 1994;285-289.
19. Annas GJ. Felal protection and employment discrimination - the Johnson Controls case. N Engl J Med. 1991;325:740-743.
20. American College of Obstetricians and Gynecologists. Statement on Thalidomide. Washington, DC: American College of Obstetricians and Gynecologists; August 27, 1997.
21. Stolberg SG. Their devil's advocate: thalidomide returns with an unlikely ally - a group of its original victims. New York Magazine. January 25, 1998:24.
22. Moore TJ. Time to act on drug safety. JAMA. 1998;279:1571-1573.
23. Sharpe R. Med Watch system comes under fire: FDA defends drug monitoring as physicians, advocates are cautious. Wall Street Journal. June 24, 1998:B5.
24. Hopkinson N. Advocacy group petitions FDA to ban diabetes drug troglitazone. Wall Street Journal. July 28, 1998:B6.
25. Daws G. Holy Man: Father Damien of Motokai. Honolulu, Hawaii: University of Hawaii Press; 1973.